

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 9, 2026

Phospho-CrkL (Tyr207) Antibody

RRID:AB_331068

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3181, RRID:AB_331068

Antibody Information

URL: http://antibodyregistry.org/AB_331068

Proper Citation: Cell Signaling Technology Cat# 3181, RRID:AB_331068

Target Antigen: Phospho-CrkL

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IHC-P, F. Consolidation on 3/2018: AB_2113018.

Antibody Name: Phospho-CrkL (Tyr207) Antibody

Description: This polyclonal targets Phospho-CrkL

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_331068

Vendor: Cell Signaling Technology

Catalog Number: 3181

Record Creation Time: 20250819T220735+0000

Record Last Update: 20250820T011131+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-CrkL (Tyr207) Antibody.

No alerts have been found for Phospho-CrkL (Tyr207) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Gu JJ, et al. (2026) ABL kinase inactivation induces transcription-replication conflicts and impairs replication fork progression in metastatic small cell lung cancer. Cell reports, 45(7), 117699.

McKernan CM, et al. (2022) ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. Cell reports, 40(9), 111268.

Luttman JH, et al. (2021) ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. Cell reports, 37(4), 109880.

Luo M, et al. (2021) Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function. Cell chemical biology, 28(4), 559.

Hoj JP, et al. (2019) A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. Cell reports, 29(11), 3421.

Eide CA, et al. (2019) Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer cell, 36(4), 431.

Morita S, et al. (2017) Targeting ABL-IRE1 γ Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes. Cell metabolism, 25(4), 883.